The Wayback Machine - https://web-wp.archive.org/web/20250512123639/https://www.nejm.org/doi/full/10.1056/NEJM198001103020221
Skip to main content

Addiction Rare in Patients Treated with Narcotics

Published January 10, 1980
N Engl J Med 1980;302:123
DOI: 10.1056/NEJM198001103020221
Editor's Note: For reasons of public health, readers should be aware that this letter has been "heavily and uncritically cited" as evidence that addiction is rare with opioid therapy. Leung et al. (https://www.nejm.org/doi/full/10.1056/NEJMc1700150) describe its history.
To the Editor: Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients1 who were monitored consecutively. Although there were 11,882 patients who received at least one narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no history of addiction. The addiction was considered major in only one instance. The drugs implicated were meperidine in two patients,2 Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.
Jane Porter
Hershel Jick, M.D.
Boston Collaborative Drug Surveillance Program Boston University Medical Center, Waltham, MA 02154

References

1.
Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind Y, Slone D. Comprehensive drug surveillance. JAMA. 1970; 213:1455–60.
2.
Miller RR, Jick H. Clinical effects of meperidine in hospitalized medical patients. J Clin Pharmacol. 1978; 18:180–8.

Information & Authors

Information

Published In

New England Journal of Medicine
Pages: 123

History

Published in issue: January 10, 1980
Published online: June 5, 2009

Authors

Metrics & Citations

Metrics

Altmetrics

Citations

Export citation

Select the format you want to export the citation of this publication.

Cited by

  1. Pain Medication in Chronic Low Back Pain, Life, 15, 5, (690), (2025).https://doi.org/10.3390/life15050690
    Crossref
  2. Opioid use and abuse in adolescents and young adults; dealing with science, laws and ethics: Charming the COBRAS, Disease-a-Month, 71, 3, (101853), (2025).https://doi.org/10.1016/j.disamonth.2025.101853
    Crossref
  3. The Impact of the Opioid Crisis on Firm Value and Investment, The Review of Financial Studies, 38, 5, (1291-1332), (2025).https://doi.org/10.1093/rfs/hhae080
    Crossref
  4. Helfer, die in die Hölle führen können: Von Opium zu Fentanyl, Chemie in unserer Zeit, (2025).https://doi.org/10.1002/ciuz.202400019
    Crossref
  5. A simple method for improving generalizability in behavioral science: Scope Testing with AI‐Generated Stimuli (STAGS), Consumer Psychology Review, 8, 1, (87-97), (2024).https://doi.org/10.1002/arcp.1101
    Crossref
  6. How a five-sentence “letter to the editor” contributed to the opioid crisis: Why meticulous citation practices are imperative, Communication Teacher, (1-7), (2024).https://doi.org/10.1080/17404622.2024.2423626
    Crossref
  7. Pain Neuroscience Education: Teaching People About Pain, Journal of Pain & Palliative Care Pharmacotherapy, 38, 3, (292-301), (2024).https://doi.org/10.1080/15360288.2024.2424853
    Crossref
  8. The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness, Health Affairs Scholar, 2, 10, (2024).https://doi.org/10.1093/haschl/qxae119
    Crossref
  9. Strategies to Deimplement Opioid Prescribing in Primary Care, JAMA Network Open, 7, 10, (e2438325), (2024).https://doi.org/10.1001/jamanetworkopen.2024.38325
    Crossref
  10. Situación actual del fentanilo en España, Medicina de Familia. SEMERGEN, 50, 6, (102255), (2024).https://doi.org/10.1016/j.semerg.2024.102255
    Crossref
  11. See more
Loading...

View Options

View options

PDF

View PDF

Media

Figures

Other

Tables

Share

Share

CONTENT LINK

Share